SALT LAKE CITY--(BUSINESS WIRE)--Lipocine Inc. (www.lipocine.com), a specialty pharmaceutical company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutic needs, today announced the successful completion of a clinical study that establishes feasibility of the first once-a-day dosing product for Ziprasidone, a leading treatment for schizophrenia and bipolar disorder.
